Anticorps Recombinant de lapin anti-IL-29

IL-29 Recombinant Antibody for FC (Intra)

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC (Intra)

Conjugaison

Non conjugué

CloneNo.

250226G7

N° de cat : 98504-1-RR

Synonymes

IL29, Cytokine Zcyto21, IFN lambda 1, IFNL1, IFN-lambda-1



Applications testées

Résultats positifs en FC (Intra)Transfected CHO cells

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98504-1-RR cible IL-29 dans les applications de FC (Intra) et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène IL-29 Protéine recombinante Eg2843
Nom complet interleukin 29 (interferon, lambda 1)
Masse moléculaire calculée22 kDa
Numéro d’acquisition GenBankNM_172140.1
Symbole du gène IL-29
Identification du gène (NCBI) 282618
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

Interleukin-29 (IL-29) is a cytokine belonging to the Type III interferon family, which has another two subfamilies IL-28A and IL-28B. They are also known as IFN-λ1, IFN-λ2 and IFN-λ3, respectively. IL-29 is produced predominantly by maturing dendritic cells and macrophages. IL-29 plays an important role in the immune response against pathogenes and especially against viruses by mechanisms similar to type I interferons. IL-29 receptor signals through JAK-STAT pathways leading to activated expression of interferon-stimulated genes and production of antiviral proteins.

Protocole

Product Specific Protocols
FC protocol for IL-29 antibody 98504-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}